Tag
TAPIS subgroup analysis reveals that ticagrelor-aspirin combined with thrombolysis may improve outcomes in moderate ischemic stroke patients with multiple acute infarcts, without increasing hemorrhage risk, suggesting infarct pattern as a p
This review synthesizes the TAILORED-CHIP trial results with recent evidence on antiplatelet modulation, highlighting the challenges of balancing ischemic and bleeding risks in high-risk PCI populations.
The TUXEDO-2 trial reveals that ticagrelor did not meet noninferiority criteria compared with prasugrel in diabetic patients with multivessel coronary artery disease undergoing PCI. At 1 year, the primary composite endpoint of death, MI, st
This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinica
